The groundbreaking success of Viagra undeniably revolutionized the drug landscape, but placing funds in companies primarily reliant on generic versions presents a challenging picture. Despite early profits were substantial, the expiration of patents and the appearance of discounted alternatives have weakened market share. Consequently, a thorough a